Viloxazine

Norepinephrine Reuptake Inhibitor — NERVOUS SYSTEM

Key facts

Viloxazine is an ofp drug in the Norepinephrine Reuptake Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Cytochrome P450 1A2 Inhibitors, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 2D6 Inhibitors. DrugCentral lists 6 molecular targets, including SLC6A3, Slc6a2 and SLC6A2. Recorded indications include Attention deficit hyperactivity disorder and Cataplexy and narcolepsy.

• Approval status: ofp (first approved 2021 by the FDA).
• Drug class: Norepinephrine Reuptake Inhibitor.
• Mechanism of action: Cytochrome P450 1A2 Inhibitors; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2D6 Inhibitors.
• Molecular targets: SLC6A3, Slc6a2, SLC6A2 and Slc6a4 (6 listed in DrugCentral).
• Indications: Attention deficit hyperactivity disorder and Cataplexy and narcolepsy.
• ATC code: N06AX09 (Other antidepressants).
• Molecular formula: C13H19NO3; molecular weight 237.30 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Attention deficit hyperactivity disorder
• Cataplexy and narcolepsy

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 1A2 Inhibitors; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inhibitors; Norepinephrine Uptake Inhibitors
• Established pharmacologic class: Norepinephrine Reuptake Inhibitor

Molecular targets (6)

Target	Gene	Action	Activity
Sodium-dependent dopamine transporter	SLC6A3	unknown	Kd 6.81
Transporter	Slc6a2	unknown	Ki 6.77
Sodium-dependent noradrenaline transporter	SLC6A2	antagonist	IC50 6.70
Sodium-dependent serotonin transporter	Slc6a4	unknown	Ki 4.78
Sodium-dependent serotonin transporter	SLC6A4	unknown	Kd 4.76
Sodium-dependent dopamine transporter	Slc6a3	unknown	Ki 4.32

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2021-04-02	FDA	—	SUPERNUS PHARMS

ATC classification

ATC code	Therapeutic hierarchy
N06AX09	NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label
• FDA label: SLCO1B1
• FDA label: CYP2D6 · Informative PGx
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Suicidal ideation	83.3
Irritability	50.3
Skin odour abnormal	47.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Viloxazine is on its molecule page.

• Molecular formula: C₁₃H₁₉NO₃
• Molecular weight: 237.30 g/mol
• CAS number: 46817-91-8
• InChIKey: YWPHCCPCQOJSGZ-UHFFFAOYSA-N
• PubChem CID: 5666

CCOC1=CC=CC=C1OCC1CNCCO1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Viloxazine used for?

DrugCentral lists the following indications for Viloxazine: Attention deficit hyperactivity disorder and Cataplexy and narcolepsy.

How does Viloxazine work?

Viloxazine is classified as Cytochrome P450 1A2 Inhibitors, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 2D6 Inhibitors; its molecular targets in DrugCentral include SLC6A3, Slc6a2, SLC6A2 (antagonist) and Slc6a4.

When was Viloxazine first approved?

Viloxazine was first approved by the FDA in 2021.

What drug class does Viloxazine belong to?

Viloxazine is in the Norepinephrine Reuptake Inhibitor class.

What is the chemical formula of Viloxazine?

Viloxazine has the molecular formula C13H19NO3 and a molecular weight of 237.30 g/mol.

Sources

• DrugCentral drug card 2820 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2106483 — compound record and bioactivity
• PubChem CID 5666 — chemical identifiers
• DrugBank DB09185 — drug record
• FDA UNII 5I5Y2789ZF — substance identity
• DailyMed: FDA labels for Viloxazine — current prescribing information (label search)
• UniProt Q01959 (SLC6A3) — target protein
• UniProt P23975 (SLC6A2) — target protein
• UniProt P31645 (SLC6A4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.